Patents Represented by Attorney, Agent or Law Firm Suzanne L. Biggs
-
Patent number: 6818616Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Also provided are recombinant Neutrophil Inhibitory Factors which also which inhibit neutrophil activity. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions and recombinant Neutrophil Inhibitory Factors are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.Type: GrantFiled: May 26, 1995Date of Patent: November 16, 2004Assignee: Corvas International, Inc.Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
-
Patent number: 6777431Abstract: The present invention provides compounds which have a pyrazinone or pyridinone ring at P3 and an optionally substituted heteroaryl group at P1. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.Type: GrantFiled: July 13, 2001Date of Patent: August 17, 2004Assignee: Corvas International, Inc.Inventors: Daniel Vanna Siev, Joseph Edward Semple, Mallareddy Komandla, John Eugene Reiner, Scott Jeffrey Kemp
-
Patent number: 6756211Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.Type: GrantFiled: May 11, 1993Date of Patent: June 29, 2004Assignee: Corvas International, Inc.Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
-
Patent number: 6586405Abstract: Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have P1 a group having an amidino or guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.Type: GrantFiled: December 7, 2000Date of Patent: July 1, 2003Assignee: Corvas International, Inc.Inventors: Joseph Edward Semple, Michael I. Weinhouse, Odile Esther Levy, Edwin L. Madison, Amir P. Tamiz
-
Patent number: 6576613Abstract: Novel inhibitors of urokinase are provided which have an arginine or arginine mimic aldehyde or an arginine ketoamide group at P1. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase.Type: GrantFiled: July 24, 1998Date of Patent: June 10, 2003Assignee: Corvas International, Inc.Inventors: Terence K. Brunck, Susan Y. Tamura, Edwin L. Madison
-
Patent number: 6573292Abstract: Methods for the treatment of Chronic Lymphocytic Leukemia and B-cell and T-cell lymphomas are provided. These methods comprise administering to a patient in need of treatment an effective amount of certain indole and carbazole compounds, such as etodolac.Type: GrantFiled: July 6, 2001Date of Patent: June 3, 2003Assignee: Salmedix, Inc.Inventor: Francis A. Nardella
-
Patent number: 6541467Abstract: The present invention provides compounds having a lactam ring at P3 and at P1 have a six-membered heterocyclic ring having two ring nitrogen ring atoms and the remainder of the ring atoms carbon atoms. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.Type: GrantFiled: April 14, 2000Date of Patent: April 1, 2003Assignee: Corvas International, Inc.Inventors: Jonathan Zhanqi Ho, Joseph Edward Semple
-
Patent number: 6534629Abstract: Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.Type: GrantFiled: February 12, 1999Date of Patent: March 18, 2003Assignee: Corvas International, Inc.Inventors: George Phillip Vlasuk, Patrick Eric Hugo Stanssens, Joris Hilda Lieven Messens, Marc Josef Lauwereys, Yves Rene LaRoche, Laurent Stephane Jespers, Yannick Georges Jozef Gansemans, Matthew Moyle, Peter W. Bergum
-
Patent number: 6506760Abstract: Compounds of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: as described herein.Type: GrantFiled: April 14, 2000Date of Patent: January 14, 2003Assignee: Corvas International, Inc.Inventors: Gian Luca Araldi, Joseph Edward Semple
-
Patent number: 6506761Abstract: Compound of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: as described herein.Type: GrantFiled: April 14, 2000Date of Patent: January 14, 2003Assignee: Corvas International, Inc.Inventors: Gian Luca Araldi, Joseph Edward Semple
-
Patent number: 6506754Abstract: The present invention provides compounds which have a pyrazinone or pyridinone ring at P3 and which feature a six member heterocyclic ring having two ring nitrogen atoms and the remainder of the ring atoms carbon atoms at P1. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.Type: GrantFiled: April 14, 2000Date of Patent: January 14, 2003Assignee: Corvas International, Inc.Inventors: Daniel Vanna Siev, Gian Luca Araldi, Jonathan Zhanqi Ho, John Eugene Reiner, Joseph Edward Semple
-
Patent number: 6432922Abstract: Novel compounds having activity inhibitors of urokinase and in reducing or inhibiting blood vessel formation are provided. These compounds have an arginine or arginine mimic aldehyde or an arginine ketoamide group at P1. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.Type: GrantFiled: July 22, 1999Date of Patent: August 13, 2002Assignee: Corvas International, Inc.Inventors: Terence K. Brunck, Susan Y. Tamura